Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 08/20/2024, as per the latest filing. These shares, valued at approximately $81,532.92, were originally acquired as founder's shares on 09/01/2016 as compensation from the issuer. This planned sale follows a series of transactions over the past three months, where Borgeson sold a total of 68,682 Class A shares, generating gross proceeds of $569,369.77. The upcoming sale continues Borgeson's pattern of share disposals, which have been regularly occurring since May 2024.

Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 08/20/2024, as per the latest filing. These shares, valued at approximately $81,532.92, were originally acquired as founder's shares on 09/01/2016 as compensation from the issuer. This planned sale follows a series of transactions over the past three months, where Borgeson sold a total of 68,682 Class A shares, generating gross proceeds of $569,369.77. The upcoming sale continues Borgeson's pattern of share disposals, which have been regularly occurring since May 2024.